; however, the findings remain controversial. The stroke risk attributable to BPV has been extensively documented in randomized trials, indicating that discrete antihypertensive drug classes have varying effects on BPV. 10, 15 Calcium channel blockers and nonloop diuretics seem to lower BPV in head-to-head comparisons with other antihypertensive drugs. 10 However, the relevance of these findings to the general population aged ≥65 years and outside of trial settings is unclear. A recent follow-up of open-label diuretic and calcium channel blocker use suggested that systolic BPV was associated with stroke in a population 65 to 84 years of age. 16 However, as only 2 classes of antihypertensive drugs were used in the intervention group, the betweenantihypertensive drug class effects on BPV and stroke were not evaluated. To date, it has not been elucidated whether antihypertensive drugs increase stroke risk independent of their effects on BPV in elderly nonrandomized controlled trials populations. This is an important limitation because in clinical practice, add-on therapy with 1 to 2 antihypertensive drugs are often required to control hypertension, and thus, BPV may be determined by several drugs.
A rterial hypertension is a primary modifiable risk factor for stroke. [1] [2] [3] However, there is no consensus as to the optimal blood pressure (BP) treatment goal in people aged ≥65 years, [4] [5] [6] [7] complicating primary prevention efforts. A large body of work outlines the prognostic association between visit-to-visit BP variability (BPV) with cardiovascular and cognitive outcomes as well as stroke. [8] [9] [10] [11] [12] Collectively, these findings question whether BPV, independent of systolic BP, should also be targeted in primary prevention efforts to reduce stroke risk 13, 14 The current study aims to examine whether antihypertensive drugs are associated with incident stroke in an older population and, second, whether their combined effect on BPV modulates stroke risk.
Methods Population
The Three-City (3C) Study is a French multisite prospective cohort study investigating the determinants of stroke and dementia. 17 Briefly, 9294 noninstitutionalized community-dwelling adults aged ≥65 years were recruited and underwent baseline neurological examinations. Serial follow-up was scheduled every 2 years, and the cohort was monitored for major disease outcomes. In the current analyses, subjects were excluded for stroke at baseline (549), lost to follow-up (n=333), not hypertensive or not antihypertensive drug users (1934), or missing BP reading at follow-up (537; Figure 1 ). Subjects lost to follow-up were more often men (P=0.042), had less education (P=0.036), and had more often smoked (P=0.046) than subjects with at least one follow-up visit. The study protocol has been approved by the Ethical Committee of the University Hospital of Kremlin-Bicêtre.
Assessment of Drug Exposure and BP
Drug use for BP was explicitly differentiated from use for other cardiovascular diseases. 18 The name of each drug was subsequently coded according to the French translation of the WHO Anatomical Therapeutic Chemical (ATC) classification. 19 Antihypertensive drug classes were α-blockers, β-blockers, calcium channel blockers (dihydropyridines and nondihydropyridines), diuretics (thiazide, high-ceiling and potassium sparing), angiotensin-converting enzyme inhibitor, and angiotensin-II receptor blockers (ARB).
Hypertension was defined as systolic BP >140 and diastolic BP >90 mm Hg and the use of an antihypertensive drug for hypertension. The meta-analysis by Tai et al 20 showed that no prospective cohort study has used the coefficient of variation method (CV-BPV) in relation to stroke. Intraindividual fluctuations in BP over 4 years with measurements at 2-year intervals was calculated using CV-BPV (please see online-only Data Supplement). CV-BPV from home BP monitoring (6 consecutive morning and 6 consecutive evening measures over 3 days) was significantly associated with clinic CV-BPV 2 years apart (β=0.217, SE=0.048; P<0.001) in a subset of 1076 participants.
Incident Stroke End Point
The protocol and criteria used to define prevalent and incident stroke have been previously defined. 21 In Bordeaux and Montpellier, all subjects underwent a comprehensive neuropsychological examination and were seen by a senior neurologist. Subjects were followed-up to 12 years for incident stroke (fatal and nonfatal). For people who reported the occurrence of vascular events during follow-up, further medical data were obtained from general practitioners, specialists, and hospital records. The diagnosis and classification of strokes were made by a blinded expert panel that reviewed all existing medical information, including, where available, cerebral imaging. Strokes subtypes included ischemic and hemorrhagic strokes according to International Classification of Diseases 10th revision criteria.
Assessment of Covariates and Moderating Variables
Baseline assessments were conducted between March 1999 and March 2001. Participants underwent face-to-face interviews using a standardized questionnaire with trained interviewers covering demographic characteristics, daily life habits, and medical history (please see online-only Data Supplement).
Statistical Analyses
In 2 separate linear regressions, we regressed antihypertensive drug classes against systolic BPV and then diastolic BPV (BPV reg ). This method accommodates the likelihood of multiple drugs contributing to BPV and polytherapy which is common in elderly real-world samples. 18 Incident stroke risk was analyzed with Cox proportional hazard models showing the hazard ratio (HR) and 95% confidence interval (CI) for each antihypertensive drug class adjusted for covariates and BPV reg . The highest attained age was used as the time scale, and participants were censored at the date of stroke, drop-out from the study, or death. We used the SPSS 22.0 complex samples function to analyze time-to-event, adjusting for late-entry bias (please see online-only Data Supplement).
Results
The final sample includes 5951 participants with a median age of 74 (interquartile range 70-78) and comprised 60% women. Incident stroke occurred in 273 participants, and there was a significant difference between the incident stroke and nonstroke group in age, mean SBP and DBP, arrhythmia, diabetes mellitus, and drug use with statins/fibrates and anticoagulants (Table 1 ). There were 2224 participants without antihypertensive medications and 3727 taking at least 1 medication for hypertension most commonly: β-blockers (20.9%), angiotensin-converting enzyme inhibitor (17.2%), potassium sparing diuretic (11.8%), ARB (10.5%), dihydropyridine calcium channel blockers (10.3%), nondihydropyridine calcium channel blockers (6.1%), high-ceiling diuretic (5.8%), α-blocker (5.7%), and thiazide diuretic (2.9%). In users of antihypertensive drugs, the proportion of monotherapy was 61.4% and polytherapy with 2 drugs was 28.5%; 3 drugs, 7.3%; and ≥4 drugs, 1.1%. Significantly higher BPV was found among all drug classes (versus nonusers) apart from thiazide and potassium-sparing diuretics (Table I in the online-only Data Supplement).
There were 48 385 person-years of survival for analysis with a median follow-up of 9.1 years (interquartile range 6.4-10.4). The annualized rate of stroke per 1000 person-years was 4.8 in the non-antihypertensive users and 6.2 in the antihypertensive medication users. Incident stroke risk was increased with ARB (HR range 1.56-1.61) and β-blocker (HR range 1.41-1.43) drug classes ( Table 2) . Entering the systolic and diastolic BPV reg coefficients minimally changed the association between incident stroke with ARB ( Figure 2A ) and β-blockers ( Figure 2B ). Only mean systolic BP increased stroke risk (per 10 mm Hg increase, HR 1.22; 95% CI 1.21-1.23; P<0.001), whereas systolic BPV reg did not (P=0.17). Similarly, diastolic BP (per 5 mm Hg increase, HR 1.12; 95% CI 1.10-1.14; P=0.003) but not diastolic BPV reg (P=0.155) was associated with stroke risk.
Stratified Analysis: Stroke Subtypes
There were 201 incident cases of ischemic stroke (3.4% of sample), and ischemic stroke risk was associated with α-blockers (HR 1.71), β-blockers (HR 1.40), and ARBs (HR 1.59) after adjustment for systolic BPV ( Figure 3 ). The ischemic stroke risk was similar among α-blocker, β-blocker, and ARB users after adjustment for diastolic BPV (Table II in 
Sensitivity Analysis
After excluding participants with untreated hypertension, the association between stroke risk with ARBs persisted (HR 1.56; 95% CI 1.01-2.41; P=0.04) but the effect size for β-blockers was attenuated (P=0.08), adjusting for systolic BPV reg . The models adjusted for diastolic BPV reg provided similar results for drug classes.
Discussion
In an elderly cohort of hypertensive people or antihypertensive drug users, we found that ARBs and β-blockers consistently increased the risk for an incident stroke. β-Blocker use increased total stroke risk ≈41% to 43%, and ARB use increased stroke risk between 56% and 61%. There was evidence of discrete associations between stroke risk and antihypertensive drug use because ARBs increased total stroke risk in systolic BP 140 to 160 mm Hg and ischemic stroke risk. On the other hand, β-blocker use increased total stroke risk in systolic ranges ≥160 mm Hg and ischemic stroke risk and failed to attain significance when untreated hypertensive participants were excluded. The common association with ischemic strokes suggests these findings were largely driven by the occurrence of this particular stroke subtype. Generally, it was evident that mean BP, rather than BPV reg , was associated with stroke risk. Collectively, the findings implicate ARB and β-blocker drug use in stroke risk, independent of medication class BPV, in an elderly French sample of hypertensives or antihypertensive drug users.
The importance of discrete drug classes and their effects on BPV to stroke risk in older population cohorts is not well documented but the current findings parallel evidence from randomized trials. The stroke risk in β-blocker randomized controlled trials is well reported. For example, a secondary analysis of the Anglo-Scandinavian Cardiac Outcomes TrialBlood Pressure Lowering Arm (ASCOT-BPLA) and Medical Research Council (MRC) trials showed that atenolol and β-blockers generally were found to increase stroke risk. 15 The ARB and β-blocker classes especially were found to increase the SD in BPV. 10 Our findings align with several prior cohort studies showing that mean BP rather than BPV is more strongly associated with adverse cardiovascular events.
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Suchy-Dicey et al 26 showed that SD BPV was predictive of all fatal and nonfatal cardiovascular outcomes aside from stroke.
Our findings implicating drug class but not BPV contrast to several recent cohort studies. In a Chinese study of 122 636 primary-care patients, it was found that diastolic as well as systolic BPV increased stroke risk using both the SD and CV method. 27 Such differences can potentially be explained by calculation of BPV. 12 It is possible that higher levels of SD BPV increase stroke risk in population samples 16 and that CV-BPV is less strongly related to stroke risk than SD BPV. The meta-analysis by Tai et al 20 showed that a 1% increased risk of stroke was attributable to a 1 mm Hg increase in SD BPV; however, only 2 included studies used this method. Another difference with prior research is that we included participants without cardiovascular comorbidities, whereas several prior studies have included participants with varying levels of stroke risk. 15, 28 For example, Shimbo et al 28 showed that the relationship between BPV and stroke was strongest in females with the lowest systolic BP (mean <120 mm Hg), whereas we included males and people with cardiovascular comorbidities and excluded people with low or untreated BP.
The clinical implications of these findings indicate that longer term BPV, as predicted from multiple drug classes, adds little to the prognostic prediction of strokes over mean BP. Considering that there is no consensus among BP guidelines for the elderly, our findings point to the likelihood that BP reduction and control remains a frontline goal for elderly people. Our study also indicated that ARB and β-blocker's association with stroke was dependent on systolic BP range and stroke subtype. Plausible mechanisms increasing stroke risk with β-blocker use relate to compensatory hemodynamic changes associated with lowered heart rate. 29 In the elderly, increased aortic stiffness and pressure wave reflection leads to increased central aortic pressures, 30 which might be exacerbated by higher stroke volume and prolongation of cardiac ejection during systole with β-blocker use. 31 Possible mechanisms through which ARBs increase stroke risk are less clear because it is purported that ARBs have neuroprotective mechanisms principally based on animal models. 32 For example, blockade of angiotensin II type 1 receptors leaving type 2 receptors unopposed leads to vasodilation. As Lévy points out, 33 however, the effects of type 2 receptor stimulation is difficult to predict from animal models, and long-term ARB use may lead to hypertrophic and antiangiogenic changes in vascular tissues.
The strengths of this study include the large representative elderly sample, the length of follow-up, a large number of incident strokes, and the serial assessment of BP over time. Several limitations temper the conclusions drawn here, including that the dosage and duration of antihypertensive drug use was not recorded, and thus, we were unable to quantify dose-response relationships. This might be particularly important because higher drug doses have been shown to reduce BPV.
14 Also, the interval between BP assessments was 2 years, which may have less prognostic value than annual, 28 ambulatory, 24-hour, and diurnal BPV. 34 A related point is that we did not incorporate drug changes into our analyses. Also, we did not assess other cognitive outcomes which might be impacted by BP lowering drugs 35 and BPV. 36 Finally, although we adjusted for comorbidities and discerned drug use for hypertension from other uses, we cannot rule out indication biases. For example, it is possible that β-blockers were favored by prescribers for their cardiovascular benefits in patients with coronary disease and acute cardiovascular event history.
Summary/Conclusions
In conclusion, ARB and β-blockers consistently increased risk for incident stroke, especially ischemic stroke. A higher stroke risk for β-blockers and ARBs was independent of mean BP and BPV. The findings suggest that BPV over the longer term is generally not associated with stroke risk in an elderly French cohort.
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